4D Molecular Therapeutics (FDMT) Competitors $8.32 -0.08 (-0.95%) Closing price 04:00 PM EasternExtended Trading$8.32 -0.01 (-0.06%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. VCEL, AVDL, GPCR, SDGR, ABCL, JANX, RCUS, SNDX, ARDX, and STOKShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Vericel (VCEL), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Schrodinger (SDGR), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors Vericel Avadel Pharmaceuticals Structure Therapeutics Schrodinger AbCellera Biologics Janux Therapeutics Arcus Biosciences Syndax Pharmaceuticals Ardelyx Stoke Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer FDMT or VCEL? In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 2 mentions for 4D Molecular Therapeutics and 1 mentions for Vericel. Vericel's average media sentiment score of 1.76 beat 4D Molecular Therapeutics' score of 1.06 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals believe in FDMT or VCEL? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 7.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is FDMT or VCEL more profitable? Vericel has a net margin of 2.85% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Vericel's return on equity of 2.47% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% Vericel 2.85%2.47%1.69% Which has higher valuation and earnings, FDMT or VCEL? Vericel has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K9,713.60-$160.87M-$3.53-2.36Vericel$237.22M7.04$10.36M$0.12275.92 Do analysts rate FDMT or VCEL? 4D Molecular Therapeutics presently has a consensus price target of $30.40, indicating a potential upside of 265.38%. Vericel has a consensus price target of $60.40, indicating a potential upside of 82.42%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55Vericel 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, FDMT or VCEL? 4D Molecular Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Summary4D Molecular Therapeutics and Vericel tied by winning 8 of the 16 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$388.54M$2.69B$6.11B$10.53BDividend YieldN/A53.56%5.51%4.67%P/E Ratio-2.3623.8285.6926.92Price / Sales9,713.60610.31583.01184.15Price / CashN/A28.3526.3031.10Price / Book0.755.5813.246.71Net Income-$160.87M$32.78M$3.30B$276.35M7 Day Performance-4.26%4.90%4.64%3.10%1 Month Performance14.44%10.52%8.36%10.19%1 Year Performance-10.15%-1.51%87.97%40.37% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.5186 of 5 stars$8.32-1.0%$30.40+265.4%-15.7%$388.54M$40K-2.36120Positive NewsVCELVericel3.1444 of 5 stars$31.79+5.2%$60.40+90.0%-22.2%$1.53B$237.22M264.94300Positive NewsAVDLAvadel Pharmaceuticals3.0621 of 5 stars$15.31-0.2%$20.86+36.2%+11.0%$1.49B$169.12M-510.3370Positive NewsGPCRStructure Therapeutics3.108 of 5 stars$25.30+1.2%$68.67+171.4%-33.3%$1.44BN/A-24.10136Positive NewsSDGRSchrodinger3.3536 of 5 stars$20.04+3.8%$27.83+38.9%+21.6%$1.42B$207.54M-8.08790Analyst DowngradeABCLAbCellera Biologics2.8825 of 5 stars$4.87+2.7%$8.00+64.3%+134.8%$1.42B$28.83M-8.85500Gap UpJANXJanux Therapeutics2.7071 of 5 stars$23.70+2.0%$78.31+230.4%-49.4%$1.40B$439K-13.1730RCUSArcus Biosciences1.9067 of 5 stars$13.34+3.9%$21.14+58.5%-12.7%$1.37B$258M-4.21500News CoverageAnalyst ForecastSNDXSyndax Pharmaceuticals3.6993 of 5 stars$15.56-0.8%$39.22+152.1%-12.9%$1.35B$23.68M-4.00110Analyst RevisionARDXArdelyx4.1112 of 5 stars$5.63+1.6%$11.70+107.8%-23.8%$1.34B$333.61M-24.4890STOKStoke Therapeutics3.1161 of 5 stars$24.73+2.4%$25.57+3.4%+127.4%$1.32B$36.56M29.09100News CoveragePositive News Related Companies and Tools Related Companies VCEL Alternatives AVDL Alternatives GPCR Alternatives SDGR Alternatives ABCL Alternatives JANX Alternatives RCUS Alternatives SNDX Alternatives ARDX Alternatives STOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
